Board Member
Collegium Pharmaceutical, Inc (COLL)Board Member
Indivior Pharmaceuticals, Inc. (INDV)Equibles does not estimate personal net worth.
Get an email with a short summary when Collegium Pharmaceutical, Inc publishes a filing, an earnings call transcript or a press release.
Get COLL alertsJoseph Ciaffoni is recorded as Board Member at Collegium Pharmaceutical, Inc (COLL), Board Member at Indivior Pharmaceuticals, Inc. (INDV) since March 4, 2025 and CEO at Indivior Pharmaceuticals, Inc. (INDV). The newest filing on record that lists Joseph Ciaffoni as Board Member at Collegium Pharmaceutical, Inc (COLL) is dated April 9, 2020. Indivior Pharmaceuticals, Inc. reported in an 8-K filed March 4, 2025 that Joseph Ciaffoni was appointed director. Indivior Pharmaceuticals, Inc. reported in an 8-K filed March 4, 2025 that Joseph Ciaffoni was appointed Chief Executive Officer. The proxy statement of Collegium Pharmaceutical, Inc reports total compensation of $10,689,852 for Joseph Ciaffoni in fiscal 2024, including a base salary of $364,423. Disclosed compensation is on record for 5 fiscal years. Joseph Ciaffoni has spoken on 8 earnings calls across 2 companies, most recently for Indivior Pharmaceuticals, Inc. on October 30, 2025. Those appearances were for Collegium Pharmaceutical, Inc (COLL) and Indivior Pharmaceuticals, Inc. (INDV). Collegium Pharmaceutical, Inc is classified in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. Indivior Pharmaceuticals, Inc. is classified in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. Other leadership on record at Collegium Pharmaceutical, Inc includes Gino Santini (Chairman and Board Member), David Dieter (General Counsel), Shirley Kuhlmann (General Counsel) and 7 others.
“Executive will, subject to any necessary shareholder approvals, serve on the Board of Directors as a director of Indivior without additional compensation and, if requested by Indivior or the Board of Directors, will hold office as a director of any affiliates of Indivior without additional compensation.”
“Executive shall serve as the Chief Executive Officer ("CEO") of Indivior plc, the parent of the Company ("Indivior"), and its subsidiaries (collectively, the "Group Companies") and have such responsibilities and authority customary for such position.”
“I'll start with a brief overview of our performance in the quarter and detail the progress we are making against the Indivior Action Agenda.”
“Today, I will start with an overview of our performance in the quarter and then introduce the Indivior Action Agenda.”
“Today, we will discuss our financial performance during the first quarter and provide an update on our progress in 2024. At Collegium, we are focused on building a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions.”
“Today, we will discuss our performance during the fourth quarter and full-year 2023 and our focus on operational execution in 2024. As we build a leading diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, we strive to do good as we do well.”
“Today, we will discuss our performance during Q2 and the first half of 2022 and provide some perspective on our outlook for the remainder of the year.”
2025-03-04–present
Start not stated–present
Last confirmed April 9, 2020
Start not stated–2024-05-24
Drug Manufacturers - Specialty & Generic · Healthcare
Board Member
Drug Manufacturers - Specialty & Generic · Healthcare
CEO, Board Member
2025-03-04–present
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2024 | Collegium Pharmaceutical, Inc (COLL) | Former President and Chief Executive Officer | $364,423 | $10,689,852 |
| 2023 | Collegium Pharmaceutical, Inc (COLL) | Former President and Chief Executive Officer | $817,038 | $9,142,924 |
| 2022 | Collegium Pharmaceutical, Inc (COLL) | Former President and Chief Executive Officer | $751,846 | $6,917,530 |
| 2021 | Collegium Pharmaceutical, Inc (COLL) | President and Chief Executive Officer | $712,754 | $7,314,335 |
| 2020 | Collegium Pharmaceutical, Inc (COLL) | President and Chief Executive Officer | $654,338 | $6,042,639 |
